Recurrent/Metastatic HNSCC: Harnessing Immunotherapy in Comprehensive Care

Subject areas

This course counts toward the state boards and subject areas below.

Disclosure statements

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD activity. CME/NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

The i3 Health planners, reviewers, and managers have nothing to disclose.

Glenn J. Hanna, MD, discloses that he has served on an advisory/board panel or as a consultant for Bicara, Bio-Rad, Boxer Capital, Bristol Myers Squibb, Coherus, Elevar, Exicure, General Catalyst, Guardian Bio, Inhibrx, KSQ Therapeutics, Kura Oncology, Maverick Therapeutics, Merck, Naveris, Nextech, PDS Biotech, Prelude, Rain Therapeutics, Regeneron, Remix, Replimune, Sanofi Genzyme, SIRPant, and Surface Oncology; and that he has received grants/research support from Actuate Therapeutics, Bicara, Bristol Myers Squibb, Elevar, Exicure, Genentech, GlaxoSmithKline, ImmunityBio, Kartos Therapeutics, Kite Pharma, KSQ Therapeutics, Kura Oncology, Regeneron, Repertoire, Sanofi Genzyme, and Secura Bio. 

Deborah Wong, MD, PhD, discloses that she has served as a consultant for Merck and Regeneron and that she has received grants/research support from AstraZeneca, Bicara Therapeutics, Bristol Myers Squibb, Checkmate, Flamingo Pharma, Genentech, Gilead, Hookipa, invoX Pharma, Kura Oncology, Lilly, Merck, Pfizer, Regeneron, and TopAlliance BioSciences. 

i3 Health has mitigated all relevant financial relationships.